Predicting Treatment Response in Patients With HR-positive, HER2-negative Breast Cancer
Presentations at the 2024 San Antonio Breast Cancer Symposium examined ways to predict responses to treatments for HR+ HER2- breast cancer.
Related Articles
Highlights of ASH®
Get a synopsis of the top hematology research presented at the latest ASH annual meeting and learn how it can help improve your patient management…
2025 Life Time Miami Marathon | Livestrong Charity Team: Run for Cancer
Run the Miami Marathon for a reason! Join Team Livestrong and your run will help cancer patients.
Travel writer takes an unexpected cancer journey
After years of guiding others on their travels, Rick Steves, a travel writer and television host based in Edmonds, Wash., took an unexpected detour after…
JNCCN 360 – Advanced Skin Cancers – Under Study in Squamous Cell Skin Cancer: Neoantigen Therapy Plus Pembrolizumab
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
AACR-QuadW Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor
The one-year grant of $50,000 supports a postdoctoral or clinical research fellow conducting translational or clinical sarcoma research.
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis
Abstract. Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly b
Vibostolimab/Favezelimab Clinical Programs in NSCLC/Lymphoma Discontinued
The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss…
Insights From the CAPTIVATE Trial on Frontline CLL Treatment Strategies
Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.
